FR 78844
FR 78844 is an orally active bone resorption inhibitor. FR 78844 attenuates metaphyseal bone mineral density decreases in Streptozotocin (HY-13753)-induced diabetic rats, and Heparin (HY-17567A)-induced osteopenia, but does not affect vitamin D-deficient rat bone loss. FR 78844 can be used for the research of osteopenia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 112856-39-0
- 分子式: C8H9NNa2O6P2S
- 分子量:355.15
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
FR 78844 potently inhibits PTH-induced calcium release from rat calvaria in vitro with an IC50 of 4.4 × 10-7 M[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) significantly attenuates ovariectomy-induced osteopenic bone loss in rats[1].
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) does not attenuate vitamin D deficiency-induced osteopenic bone loss in rats[1].
FR 78844 (1-100 mg/kg; p.o.; 5 days a week; 4 weeks) dose-dependently attenuates Heparin-induced osteopenia in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (9-week-old female; Streptozotocin (STZ)-induced diabetic model)[1]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Attenuated the decrease in femur metaphyseal bone mineral density by 66% at 100 mg/kg dose compared to vehicle-treated STZ rats.
Did not produce a significant effect at 1 mg/kg and 10 mg/kg doses.
-
Animal Model:Wistar rats (9-week-old female; ovariectomized model)[1]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Attenuated the decrease in femur metaphyseal bone mineral density by 81% at 100 mg/kg dose compared to vehicle-treated ovariectomized rats.
Did not produce a significant effect at 1 mg/kg and 10 mg/kg doses.
-
Animal Model:Wistar rats (4-week-old female; vitamin D-deficient model)[1]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Did not produce a significant effect on femur metaphyseal bone mineral density at any tested dose compared to vehicle-treated vitamin D-deficient rats.
-
Animal Model:Wistar rats (female, 9 weeks old, osteopenia induced by Heparin sodium 2000 U/kg·day subcutaneously 5 days a week for 4 weeks)[2]
-
Dosage:1; 10; 100 mg/kg
-
Administration:p.o.; 5 days a week; 4 weeks
-
Result:Attenuated the heparin-induced decrease in metaphyseal bone mineral density in a dose-dependent manner.
Produced a significant increase in metaphyseal bone mineral density at 100 mg/kg compared to the vehicle-treated heparinized group.
Showed a significant improvement in metaphyseal bone mineral density at 10 mg/kg relative to the vehicle group.
化学情報
-
CAS 番号 112856-39-0
-
分子量 355.15
-
分子式 C8H9NNa2O6P2S
-
SMILES
S=C(NC1=CC=CC=C1)C(P(O)(O)=O)P(O[Na])(O[Na])=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Takeshita N, et al. Possible involvement of vitamin D3-deficiency and relatively enhanced bone resorption in the development of bone loss in streptozotocin-induced diabetic rats. Life Sci. 1994;55(4):291-9. [Content Brief]
[2]. Mutoh S, et al. Characterization of heparin-induced osteopenia in rats. Endocrinology. 1993 Dec;133(6):2743-8. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
FR 78844 関連分類
HY-122075 関連分類
Powered by Bioz